Companies › PolyActiva
2 active drug programs in 2 registered trials: 1 Phase 2, 1 Phase 1; Ophthalmology; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| PA5108 Ocular Implant unclear - combination product for ocular delivery | – | Phase 2 | Glaucoma, Open-Angle | Nov 2026 |
| PA5346 Ocular Implant Biodegradable ocular implant for intraocular pressure reduction | – | Phase 1 | Open Angle Glaucoma (OAG) | Feb 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06964191 | PA5108 Ocular Implant | Phase 2 | Glaucoma, Open-Angle | Ophthalmology | Nov 2026 |
| NCT06964061 | PA5346 Ocular Implant | Phase 1 | Open Angle Glaucoma (OAG) | Ophthalmology | Feb 2027 |
No annotated target.
–
Vantage Biosciences Tourmaline Bio, Inc., a Novartis Company Sunhawk Vision Biotech Qingdao WanMing BioCell Pharmaceutics Caravel Oculus
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.